Vanguard Group’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $305M | Sell |
|
|||||
|
2025
Q2 | $371M | Buy |
|
|||||
|
2025
Q1 | $362M | Sell |
|
|||||
|
2024
Q4 | $422M | Buy |
|
|||||
|
2024
Q3 | $552M | Buy |
|
|||||
|
2024
Q2 | $402M | Buy |
|
|||||
|
2024
Q1 | $406M | Buy |
|
|||||
|
2023
Q4 | $415M | Buy |
|
|||||
|
2023
Q3 | $258M | Buy |
|
|||||
|
2023
Q2 | $324M | Buy |
|
|||||
|
2023
Q1 | $271M | Buy |
|
|||||
|
2022
Q4 | $295M | Buy |
|
|||||
|
2022
Q3 | $255M | Buy |
|
|||||
|
2022
Q2 | $366M | Buy |
|
|||||
|
2022
Q1 | $433M | Buy |
|
|||||
|
2021
Q4 | $498M | Buy |
|
|||||
|
2021
Q3 | $530M | Buy |
|
|||||
|
2021
Q2 | $540M | Sell |
|
|||||
|
2021
Q1 | $671M | Buy |
|
|||||
|
2020
Q4 | $782M | Buy |
|
|||||
|
2020
Q3 | $440M | Buy |
|
|||||
|
2020
Q2 | $402M | Buy |
|
|||||
|
2020
Q1 | $221M | Buy |
|
|||||
|
2019
Q4 | $207M | Sell |
|
|||||
|
2019
Q3 | $217M | Buy |
|
|||||
|
2019
Q2 | $318M | Buy |
|
|||||
|
2019
Q1 | $339M | Buy |
|
|||||
|
2018
Q4 | $181M | Buy |
|
|||||
|
2018
Q3 | $309M | Sell |
|
|||||
|
2018
Q2 | $313M | Buy |
|
|||||
|
2018
Q1 | $201M | Buy |
|
|||||
|
2017
Q4 | $147M | Buy |
|
|||||
|
2017
Q3 | $167M | Buy |
|
|||||
|
2017
Q2 | $194M | Buy |
|
|||||
|
2017
Q1 | $203M | Buy |
|
|||||
|
2016
Q4 | $199M | Buy |
|
|||||
|
2016
Q3 | $189M | Buy |
|
|||||
|
2016
Q2 | $127M | Buy |
|
|||||
|
2016
Q1 | $156M | Buy |
|
|||||
|
2015
Q4 | $269M | Buy |
|
|||||
|
2015
Q3 | $204M | Buy |
|
|||||
|
2015
Q2 | $178M | Buy |
|
|||||
|
2015
Q1 | $99M | Buy |
|
|||||
|
2014
Q4 | $57.5M | Buy |
|
|||||
|
2014
Q3 | $61.7M | Buy |
|
|||||
|
2014
Q2 | $12.3M | Buy |
|
|||||
|
2014
Q1 | $10.5M | Buy |
|